SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
5 of
5
|
SESSION OVERVIEW-LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?
Babafemi Taiwo
Northwestern University, Chicago, IL, United States
PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTEGRAVIR/RILPIVIRINE (ABSTRACT
516)
Stephanie Kenney
University of California San Diego, San Diego, CA, United States
HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION (ABSTRACT
518)
Monica Gandhi
University of California San Francisco, San Francisco, CA, United States
PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART (ABSTRACT
517)
Wanyi Chen
Harvard Medical School, Cambridge, MA, United States
DISCUSSION WITH ANSWERS TO AUDIENCE QUESTIONS
Babafemi Taiwo
Northwestern University, Chicago, IL, United States
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
5 of
5
|
